ROCKWOOL A/S
Total number of voting rights and share capital in ROCKWOOL A/S
Total number of voting rights and share capital in ROCKWOOL A/S
Company announcement
for ROCKWOOL A/S
Release no. 34 – 2025
to Nasdaq Copenhagen
28 May 2025
Total number of voting rights and share capital in ROCKWOOL A/S
On 2 May 2025, ROCKWOOL A/S (“the Company”) completed a reduction of its share capital by nominally 4,601,300 DKK. The reduction was carried out by cancellation of treasury B shares in accordance with the resolution adopted at the Company’s Annual General Meeting on 2 April 2025.
In accordance with Section 32 of the Danish Capital Market Act, the Company is required to disclose the total number of voting rights and shares in the event of changes. Following completion and registration of the capital reduction, the Company’s share capital and total number of voting rights are as follows:
Share capital (nominal value, DKK) | Number of shares (of 1 DKK each) | Number of votes | |
Class A shares | 98,178,390 | 98,178,390 | 981,783,900 |
Class B shares | 113,427,400 | 113,427,400 | 113,427,400 |
Total | 211,605,790 | 211,605,790 | 1,095,211,300 |
Further information:
Kim Junge Andersen
Senior Vice President, CFO
ROCKWOOL A/S
+45 46 55 80 15
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Gatorade31.5.2025 17:39:49 CEST | Press release
Gatorade 5v5 Finals Bring Global Youth to Champions League Stage in Munich
F. Hoffmann-La Roche Ltd31.5.2025 14:05:00 CEST | Press release
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
Ipsen Pharma31.5.2025 14:00:00 CEST | Press release
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
WithSecure Oyj31.5.2025 08:45:00 CEST | Press release
WithSecure has completed the transaction of Cyber security consulting divestment to Neqst
Teva Pharmaceutical Industries Ltd31.5.2025 03:05:00 CEST | Press release
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom